Liquidia Corporation: Business Overview, Financials & Competitive Analysis
Liquidia Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). Liquidia is a pre-revenue-to-profitable inflection biotech with a validated lead product gaining rapid traction in a significant rare disease market, supported by differentiated PRINT® technology. The company achieved profitability in the first full quarter of YUTREPIA sales with $51.7 million in net product sales, demonstrating successful commercialization. LQDA exceeded both.
What is Liquidia Corporation's industry? Liquidia Corporation (liquidia.com) operates in Biopharmaceutical - Specialty Pharmaceuticals (Pulmonary Hypertension). AskCyborg classifies Liquidia Corporation under Biopharmaceutical - Specialty Pharmaceuticals (Pulmonary Hypertension) in its company registry.
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, with a current focus on the development and commercialization of products in pulmonar...
Cyborg Score thesis
Liquidia is a pre-revenue-to-profitable inflection biotech with a validated lead product gaining rapid traction in a significant...
Read the full analyst-debate transcript →Get the Latest Liquidia Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeLiquidia Corporation Overview
Pro stress-test →Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, with a current focus on the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. The company achieved momentum with YUTREPIA net product sales of approximately $148.3 million for full-year 2025, generating more than 2,800 unique patient prescriptions since launch in June 2025.
Strategic Profile
Pro stress-test →Liquidia develops innovative therapies using its proprietary PRINT® Technology for precise drug particle engineering, which enables the scalable production of uniform drug particles and optimal deposition in the lungs. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Competitive Landscape
Pro stress-test →Liquidia distinguishes itself through its unique PRINT® technological platform and rigorous quality standards, with its scalable process combined with robust clinical research and strategic partnerships offering a scientifically sound alternative in a market with significant unmet needs. The company competes in the rare pulmonary hypertension market against established therapies and other biopharmaceutical developers focusing on PAH and PH-ILD treatments.
Industry Context
Liquidia Corporation operates in Biopharmaceutical - Specialty Pharmaceuticals (Pulmonary Hypertension).
Key facts
Founded: 2004 · Headquarters: Morrisville, North Carolina · Revenue: $148.3M (2025 YUTREPIA sales) · Market cap: $2.2B